The market is sleeping on this one. Pitney Bowes is primed for a massive turnaround with potential to sky rocket in the short term and triple in value over the next 2 years. I’m betting on them with shares, short…
Landbridge recently IPO’d on June 28th and I think their business model presents an interesting growth opportunity. So who are they? Founded in 2021, Landbridge owns about 220,000 acres of land across Texas and New Mexico in the Permian Basin…
Just to be clear this is not financial advice, and there are more factors than an earnings beat that affect stock price, but this is why I think NVDA will beat revenue predictions of $28B on Aug 28th 2024. As…
NurExone Biologics is developing exosome-based therapies for non-invasive treatment of central nervous system injuries, with their lead product, ExoPTEN, showing significant promise in preclinical trials. The company is expanding its research into optic nerve regeneration, with a study initiated by…
Last week, I told you guys what to do for both META and AMZN. This week we have more earnings, specifically today I wanted to look at HOOD. Let’s just first take a quick glance at the company, Robinhood Markets. They’ve been expanding…
A yen carry trade is a popular currency trading strategy that involves borrowing money in Japanese yen at low interest rates and investing it in assets or currencies with higher yields. Here are the key aspects of a yen carry…
Hawaiian Electric Industries (HAWEL) has recently reached a tentative settlement agreement to pay approximately $4 billion to resolve hundreds of lawsuits related to the devastating Maui wildfires of August 2023. This settlement is part of a larger resolution involving multiple…
Intel Corporation, once a dominant force in the tech industry, is now grappling with a series of significant challenges that have fueled a troubling decline. Despite attempts to project a positive outlook, the company’s current trajectory suggests a troubling downward…
HIMS is a stock that had gotten some steam recently with it’s over 100% run this year, but has cooled down after trading in its $20-24 dollar range for a few weeks. I’m going to explain why a stock I…
Zevra Therapeutics Inc. (NASDAQ: ZVRA), a pioneering company focused on rare disease therapeutics, made significant headlines today. The company is at the forefront of developing treatments for conditions with limited or no current therapeutic options, leveraging science, data, and patient…